Ipca Laboratories, a Rs.2,725 crore plus pharma major, has posted standalone earnings before depreciation, interest, tax and adjustments (EBDITA) of Rs.239.86 crore during the second quarter ended September 2013 as compared to Rs.187.97 crore in the similar period of last year, a strong growth of 27.6 per cent. Its net profit improved only by 3.5 per cent to Rs.129.45 crore from Rs.125.09 crore mainly due to foreign exchange loss of Rs.39.91 crore as against a profit of Rs.6.38 crore in the last period. Its net sales moved up by 10.1 per cent to Rs.834.27 crore from Rs.757.52 crore.

The board of director has recommended interim dividend of 125 per cent (Rs.2.50 per share of Rs.2 each). After the announcement of financial performance and interim dividend, Ipca scrip increased by 2.07 per cent or Rs.13.75 to Rs.678.05 on the Bombay Stock Exchange.

The company's Indian formulations income increased by 5 per cent to Rs.276.17 crore and formulation exports increased by 7 per cent to Rs.362.64 crore from Rs.339.16 crore. Similarly, the sales of domestic APIs increased by 33per cent to Rs.40.49 crore and API exports by 24 per cent to Rs.154.97 crore. its export income up by 11 per cent to Rs.517.61 crore.

For the first half ended September 2013, Ipca's net sales increased by 17.2 per cent to Rs.1,627 crore from Rs.1,388 crore and its net profit moved up by 19.7 per cent to Rs.201.22 crore from Rs.168.07 crore.